rilzabrutinib
AssetAlso PRN1008, Wayrilz
Inhibits Bruton tyrosine kinase to reduce immune-mediated platelet destruction.
- Stage
- Approved
- Modality
- Small molecule
- Target
- BTK
- 8
- Indications
- 7
- Trials
- 3
- Developers
Indications
8Immune thrombocytopenia
Approved, mixonline.jp, Oct 21, 2026
Persistent and chronic immune thrombocytopenia
Approved, yakuji.co.jp, Oct 25, 2026
Autoimmune hemolytic anemia
Phase 3, Recruiting, NCT07086976, clinicaltrials.gov, Oct 22, 2026
5 more
In the full profile
- Targets and what it contains1
- Owner and partners3
- Trials7
- Evidence for its targets1
- Competitors12
- Signals7
Every asset’s record: target, stage, trials and the evidence behind it.